Stem cells are real medicine and real science. They are also one of the most aggressively over-marketed areas in modern health. The same phrase — “stem cell therapy” — can mean a hospital bone-marrow transplant that saves a leukemia patient, an FDA-approved cord-blood product for blood disorders, an experimental clinical trial, a cash-pay joint injection, a celebrity anti-aging testimonial, or an overseas clinic selling broad claims for conditions where proof is still weak.
Medical caution
This article is education and source review. It is not medical advice, diagnosis, treatment guidance, a clinic endorsement, or an instruction to travel for therapy. Stem-cell decisions belong with qualified physicians, regulators, ethics-approved clinical trials, and disease specialists.
Weekly update — October 12, 2026
Regulated transplant medicine reaches routine use: in an October 7 report, Stanford says it administered the first commercial Orca-T treatment, marketed as Tregzi. This is an implementation milestone, not a new October approval or a proven outcome for that patient. FDA approved Tregzi on June 30, 2026 for matched-donor hematopoietic stem-cell transplantation with a myeloablative preparative regimen in adults with hematologic malignancies. In the randomized Precision-T trial, the estimated 12-month incidence of moderate-to-severe chronic graft-versus-host disease was 12.6% with Tregzi versus 44.0% with the comparison transplant regimen. Infection, graft failure, GVHD and other serious risks remain. Evidence label: approved for a narrow indication, not support for broad commercial regenerative infusions.
Survival does not mean recovery is finished: an October 11 Danish nationwide study of patient-reported late effects included 895 allogeneic-transplant survivors, with a median seven years since transplantation. Fatigue was reported by 90%, and 38% exceeded thresholds for clinical importance in at least five symptom or functioning domains. This cross-sectional survey describes a substantial long-term burden; it does not establish that transplantation caused every symptom or compare today's specific transplant products. Evidence label: observational human survivorship evidence.
Catch-up since the September 21 review — Parkinson's: the September 23 REPOSE pilot trial randomized 40 participants to intravenous adipose-derived cells or placebo, with rehabilitation in both groups. No exploratory efficacy endpoint remained statistically significant after adjustment for multiple comparisons. A thromboembolic event in the cell-treatment group had an uncertain relationship to treatment; the small study cannot exclude uncommon harms. Sponsor affiliations were disclosed. This is under study; efficacy not demonstrated, not a Parkinson's cure. It is a different product and approach from Japan's conditionally approved iPSC-derived dopaminergic-cell product.
Catch-up — type 1 diabetes: a September 30 randomized phase 1 trial of gingiva-derived mesenchymal cells enrolled 18 participants. The authors report improved C-peptide measures of residual insulin production and reduced insulin requirements at 12 weeks, with similar glycemic control between groups. The small sample and short assessment window do not establish durable benefit or rare-event safety. This is immune-modulation research, not a demonstration of stem-cell-derived islet replacement or a general diabetes cure. Evidence label: promising/under study; not a reason to alter prescribed treatment.
October 12 source note: sources checked, catch-up window, evidence limits and unchanged conclusions. No dosing, clinic endorsement or medical-tourism recommendation.
Weekly update — September 21, 2026
Long-term human follow-up, not a general cure: a September 16 Ophthalmology Retina report follows one patient ten years after an autologous iPSC-derived retinal pigment epithelium sheet transplant. Imaging showed persistent graft-associated pigmentation and preservation of adjacent retinal and choroidal structures. This is valuable long-term structural follow-up, but a single patient cannot establish how often treatment works, reliably quantify rare harms, or prove restored vision. Evidence label: promising/under study.
Multiple sclerosis: biological activity is not clinical benefit. A new MSC-derived neural-progenitor biomarker study found changes in four cerebrospinal-fluid markers, while neurofilament light and GFAP were unchanged. A separate MESEMS immune-cell analysis reports immune changes but explicitly notes that the parent trial did not demonstrate a significant effect on MRI disease activity. Neither report establishes an MS cure or validates commercial MSC infusions.
COPD research milestone, company-reported: on September 16, SMSbiotech announced FDA permission to proceed with a U.S. early-phase inhaled-cell study. That is not marketing approval or proof of lung regeneration. The separately registered Australian SORT-COPD study is phase 1, non-randomized and open-label, with no results posted when checked. Its listing does not independently authenticate the company's U.S. regulatory announcement.
Japan clarification — earlier approval, newly documented here: PMDA lists AMCHEPRY and RiHEART as approved in March 2026. Their official review reports specify conditional, seven-year approvals for narrow indications, with further efficacy evaluation and all-patient surveillance. These are not new September approvals, universal cures or endorsements of medical tourism. The country table below now distinguishes these products from unapproved clinic offerings.
Full September 21 source note, evidence labels and access limitations. No medical advice, dosing instructions or clinic recommendations.
Weekly source check — September 14, 2026
A newly indexed New England Journal of Medicine pediatric report on exa-cel in children ages 5–11 with transfusion-dependent β-thalassemia or sickle cell disease is a meaningful regulated-cell-therapy update. Among children followed long enough for the primary endpoints, 8/8 with β-thalassemia were transfusion independent and 8/8 with sickle cell disease were free of severe vaso-occlusive crises for at least 12 months. The caution is equally important: every treated child had at least one grade 3 or 4 adverse event, and one death was assessed as related to busulfan conditioning. Evidence label: disease-specific, high-intensity specialist medicine — not support for broad commercial stem-cell clinic claims. A small first-in-human glycocalyx-edited MSC osteoporosis trial and a knee-osteoarthritis MSC responder analysis remain promising/under-study signals, not general approvals. This week's source note is preserved at stem-cells-weekly-update-2026-09-14.md.
Weekly source check — September 7, 2026
FDA's recent R3 Medical Companies warning letter is a useful safety and enforcement update. FDA alleged that several umbilical-cord-derived and claimed exosome products were unapproved new drugs/unlicensed biological products, cited manufacturing-practice concerns, and pointed to broad marketing claims around inflammation, arthritis, COPD, neurologic conditions, diabetes, erectile dysfunction and other uses. The evidence label does not change: this is an official enforcement signal, not proof that commercial stem-cell, Wharton’s jelly, umbilical-cord or exosome clinic offerings work. A new ClinicalTrials.gov Parkinsonism registry lead also remains a trial listing only, not clinical proof. This week's source note is preserved at stem-cells-weekly-update-2026-09-07.md.
Weekly source check — August 31, 2026
FDA's Approved Cellular and Gene Therapy Products page is now marked content current as of August 18, 2026. That is a meaningful official-list update, but it does not change the core caution: approvals remain product-specific and indication-specific, not a blanket approval for cash-pay stem-cell, exosome, orthopedic, anti-aging, neurologic or medical-tourism clinic claims. A new orthobiologic knee-injection pricing study is also useful market context — the abstract reports stem-cell injections were concentrated in alternative clinics and median listed prices varied — but pricing visibility is not evidence of clinical benefit. This week's source note is preserved at stem-cells-weekly-update-2026-08-31.md.
Weekly source check — July 27, 2026
A newly indexed Nature Medicine phase 1 report on iPSC-derived neural progenitor cells for subacute spinal cord injury is a meaningful safety/feasibility signal: four patients, open-label design, 2–4 years of follow-up, no tumor formation or graft-related adverse events reported, and exploratory motor-score gains. It should still be read as promising/under study, not proof of a broadly available spinal-cord cure or endorsement of commercial clinic claims. A new MSC Alzheimer’s systematic review/meta-analysis also reinforces caution: current clinical evidence remains insufficient to confirm efficacy and most evidence was low to very-low certainty. This week’s source note is preserved at stem-cells-weekly-update-2026-07-27.md.
Weekly source check — July 6, 2026
FDA’s Approved Cellular and Gene Therapy Products page is now marked content current as of July 1, 2026. That is a meaningful regulatory-list update, but it does not change the core Managing Expectations frame: approved cellular and gene therapies are product-specific and indication-specific. It is not a blanket approval for cash-pay “stem cell,” exosome, orthopedic, anti-aging, neurologic or medical-tourism clinic claims. This week’s source note is preserved at stem-cells-weekly-update-2026-07-06.md.
The bottom line first
- Proven core use: blood-forming stem cell transplantation — bone marrow, peripheral blood stem cells, or cord blood — is established for certain blood cancers, blood disorders, immune disorders and some autoimmune contexts under specialist care.
- Approved products are narrow: FDA-approved cellular/gene products include cord-blood hematopoietic progenitor cell products, CAR-T therapies, gene therapies, cultured chondrocytes and other condition-specific products. That is not the same as broad approval for “stem cells” for arthritis, aging, dementia, COPD or general wellness.
- Celebrity testimony is not proof: stories from Jack Nicklaus, Peyton Manning, Mel Gibson/Joe Rogan and athlete clinics explain why people are interested. They do not replace randomized trials, registries, regulator approval or long-term safety data.
- Most cash-pay regenerative clinics sell promise before proof: especially for anti-aging, autism, Parkinson’s, dementia, COPD, erectile dysfunction, chronic pain, “immune reset,” cosmetic rejuvenation and cancer cure-all claims.
- Risks are not theoretical: FDA says it has received reports of blindness, tumor formation, infections and other serious harms from unapproved regenerative products.
What are stem cells?
Stem cells are cells with two important properties: they can renew themselves, and they can develop into more specialized cell types. NIH divides the field into major categories: pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells, and adult or somatic stem cells found in tissues and organs. The key practical point is that different stem cells are not interchangeable. A blood-forming stem cell is not the same thing as a mesenchymal stromal cell, a fat-derived cell mixture, an exosome product, or a lab-derived induced pluripotent stem cell line.
Marketing often collapses all of this into one phrase: “stem cells heal.” That is too simple. The real question is: which cell type, from what source, processed how, tested for what, delivered where, for which diagnosis, under what regulatory authority, with what evidence?
Two very different worlds: transplant medicine vs. regenerative clinic marketing
| Category | What it usually means | Evidence status |
|---|---|---|
| Hematopoietic stem cell transplant | Bone marrow, peripheral blood stem cells or cord blood to rebuild blood/immune production after high-dose chemotherapy/radiation or for certain blood/immune disorders. | Established specialist medicine. High-risk, expensive, often lifesaving or disease-altering in the right indication. |
| Approved cell/gene products | Condition-specific products such as CAR-T therapies, cord-blood HPC products, gene therapies, cultured chondrocytes and other regulated products listed by FDA. | Approved only for specific indications, labels and patient groups. |
| Orthopedic stem-cell injections | Bone marrow concentrate, adipose-derived products, stromal vascular fraction or related injections into joints/tendons/spine. | Some biologic plausibility and studies; many uses remain investigational. AAOS urges caution. |
| MSC / umbilical cord / exosome clinics | Commercial infusions or injections for inflammation, aging, neurologic, lung, autoimmune, sexual health or general wellness claims. | Often cash-pay and not approved for the advertised broad claims. Evidence varies from early trials to unsupported marketing. |
| Embryonic/iPSC-derived therapies | Lab-derived cells for retina, diabetes, Parkinson’s, spinal cord injury and organ repair research; selected products have jurisdiction-specific authorization. | Many remain under study. Japan's AMCHEPRY and RiHEART have conditional, time-limited approval for narrow indications; see the official reports in the country table. Tumor, immune, manufacturing and durability questions remain product-specific. |
What stem cells are used for today
1. Blood cancers and blood disorders
The strongest, most established use is hematopoietic stem cell transplant. NCI explains that these procedures restore blood-forming stem cells destroyed by high-dose chemotherapy or radiation used to treat certain cancers, blood disorders and autoimmune disorders. They are most often used for blood-cell cancers such as leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes, and for other blood disorders such as aplastic anemia and sickle cell disease.
There are three main transplant types. Autologous means your own cells are collected and returned. Allogeneic means donor cells are used and must be matched. Syngeneic means cells from an identical twin. Allogeneic transplants can add an immune attack on remaining cancer cells, but they also create risk of graft-versus-host disease, rejection, infections and long immune recovery.
2. Cancer immunotherapy and cell therapy
Some modern cancer treatments are not “stem-cell cures” but are cellular therapies. CAR-T therapy, for example, engineers a patient’s immune cells to attack cancer targets. FDA’s approved cellular/gene therapy list includes multiple CAR-T products and other condition-specific products. The lesson: cell therapy is real, but every product has a precise label, manufacturing process, indication and risk profile.
3. Orthopedics and pain
Back pain, knees, shoulders, tendons and arthritis drive huge demand. Famous athlete stories keep this market alive. But orthopedics is where evidence and marketing often separate. AAOS notes that only a few types of stem-cell treatments have FDA approval and that ongoing clinical trials are testing safe and effective uses. In practical terms: a patient may report pain relief after a procedure, but pain relief does not automatically prove cartilage regeneration, tissue rebuilding, long-term disease modification or superiority to rehab/surgery/placebo.
4. Autoimmune and inflammatory disease
Hematopoietic stem cell transplantation is being used or studied in select severe autoimmune contexts. The logic is immune “reset”: intense treatment suppresses or destroys parts of the immune system, then stem cells rebuild it. This is not a casual wellness infusion. It can involve hospitalization, infection risk, infertility risk, organ toxicity and long follow-up. Mesenchymal stromal cells are also studied for inflammatory signaling, but broad commercial claims are ahead of settled evidence.
5. Neurologic, anti-aging and organ-regeneration claims
Parkinson’s, spinal cord injury, stroke, dementia, macular degeneration, diabetes, COPD, kidney disease and aging are the frontier that attracts hope. Some areas have legitimate trials. But hope is not approval. The more dramatic the claim — “walk again,” “reverse dementia,” “regrow organs,” “cure autism,” “anti-aging reset” — the more the reader should ask for published human data, trial registration, ethics approval, adverse-event reporting, regulator status and long-term follow-up.
How stem cells are applied to the body
- IV infusion: common for blood stem cell transplant and many commercial MSC/cord-cell clinics. In transplant medicine, cells are infused through an IV catheter; NCI says receiving the stem cells can take 1 to 5 hours. For commercial infusions, the concern is whether cells lodge in lungs/other tissues, what they actually do, and whether the product is sterile, characterized and legally authorized.
- Direct injection: joints, tendons, spine/facet joints, discs or injury sites. Celebrity orthopedic stories often involve direct injections. Risks include infection, bleeding, nerve injury, worsening pain, and unproven durability.
- Intrathecal / spinal delivery: used in some neurologic clinic claims. Higher risk because it involves the central nervous system; should demand extraordinary evidence and oversight.
- Local surgical placement: some approved tissue-engineered products are placed surgically for specific indications.
- Conditioning then transplant: for HSCT, patients may receive chemotherapy/radiation conditioning, then “day zero” infusion, then weeks to months of recovery and monitoring.
Timelines and recovery
| Treatment type | Typical timeline | Recovery reality |
|---|---|---|
| Hospital HSCT | Evaluation, collection/donor matching, conditioning, day-zero infusion, inpatient/outpatient monitoring. | Blood counts recover first; immune recovery is much longer. NCI notes several months for autologous and 1–2 years for allogeneic/syngeneic immune recovery. |
| Orthopedic injection | Often same-day harvest/process/inject or donor-product injection; follow-up over weeks/months. | Pain may flare initially. Improvement claims range from weeks to months. Structural regeneration is much harder to prove than symptom change. |
| IV commercial MSC/cord-cell program | Often multi-day clinic visits with screening, infusions and adjunctive treatments. | Testimonials often describe energy/pain/inflammation changes. Independent durability and disease-modification evidence may be limited. |
| Clinical trial | Screening, consent, baseline tests, intervention, scheduled follow-up and adverse-event monitoring. | Best path for uncertain indications because outcomes and harms are tracked under protocol. |
Reported improvements people seek
People seek stem-cell or regenerative treatments for pain reduction, inflammation reduction, improved mobility, faster injury recovery, immune modulation, tissue repair, improved energy, neurologic function, lung function, cardiac function, cognition, sexual health, skin/hair/cosmetic rejuvenation and anti-aging. The critical Managing Expectations distinction is that reported improvement can come from many things: natural recovery, rehabilitation, placebo/context effects, reduced inflammation, pain-modulation, other treatments given at the same clinic, changes in training, or the cell product itself. A testimonial can be honest and still not prove the mechanism.
Famous users and testimonies: useful leads, not verdicts
| Person | Claim/source | How to read it |
|---|---|---|
| Jack Nicklaus | CNN and New Scientist reported Nicklaus received experimental fat-derived stem-cell treatment in Munich for chronic back pain and later spoke positively about the result. | Powerful anecdote from a credible public figure; not a randomized trial. It supports curiosity, not general proof that the same method works for all back pain. |
| Peyton Manning | ESPN covered Manning being linked to stem-cell therapy in Europe around neck-injury treatment. | Elite-athlete access story. Multiple interventions and recovery variables make causal proof difficult. |
| Mel Gibson / Joe Rogan / Dr. Neil Riordan | A widely circulated Joe Rogan discussion and clinic-hosted material describe Gibson’s father improving after treatment in Panama. | Major testimonial with strong emotional force. It is also clinic-adjacent promotional material and not controlled medical evidence. |
| Athletes broadly | Many articles and clinic pages list athletes who explored stem cells, PRP, Regenokine or other regenerative procedures. | Be careful: PRP, platelet products, orthobiologics and stem cells are often mixed together in popular articles. “Athlete used it” does not equal “approved cure.” |
Pricing: what people actually pay
Prices vary because the phrase “stem cell therapy” covers hospital transplant, regulated cell therapy, orthopedic procedures and overseas cash-pay clinics. Published numbers are often not apples-to-apples.
- Hospital hematopoietic transplant: U.S. cost studies report very high 100-day costs. Broder et al. reported median 100-day healthcare costs around $140,792 for an autologous cohort and $253,467–$289,283 for allogeneic cohorts, depending on regimen. Majhail et al. reported median 100-day total costs around $99,899 for autologous and $203,026 for allogeneic HCT in an earlier analysis.
- Insured specialist treatment: patient out-of-pocket cost depends on insurance, country, hospital system, indication, complications, donor search and drugs.
- U.S. cash-pay orthopedic/regenerative clinics: often several thousand to tens of thousands of dollars per joint/procedure; coverage is inconsistent and many uses are considered investigational.
- Mexico cash-pay example: R3/Stem Cell Mexico publicly advertised treatments starting at $4,950 for 25 million stem cells with a pricing notice updated June 1, 2026. This is marketing price information, not proof of benefit.
- Panama/Colombia/Cayman/Europe private clinics: frequently quote after application/consult. Multi-day programs can run from thousands to tens of thousands of U.S. dollars plus travel, lodging and follow-up. Published clinic testimonials should not be treated as independent outcomes data.
Regulation and locations
| Location | Regulatory reality | Patient caution |
|---|---|---|
| United States | FDA regulates regenerative products. FDA warns that many marketed stem-cell, exosome, amniotic, Wharton’s jelly and stromal vascular products require approval or FDA-overseen clinical trials. Tregzi's June 30, 2026 approval is a specific example: matched-donor hematopoietic transplantation with a myeloablative preparative regimen in adults with hematologic malignancies, for hematopoietic and immunologic reconstitution and improved chronic GVHD-free survival. It is not approval of unrelated clinic products. | Ask whether the exact product/procedure is FDA-approved for your diagnosis or part of an FDA-authorized trial. |
| Canada | Health Canada has warned about unauthorized cell therapies and has regulated many cell therapies as drugs/biologics. Its 2019 alert warned of serious infection and life-altering risks. | Ask whether Health Canada has authorized the product for the condition, and whether it is a legitimate trial. |
| Mexico / Panama / Colombia / Cayman | Major destinations for medical tourism and clinic-marketed MSC/umbilical-cord/exosome programs. Local rules vary; some clinics advertise GMP labs and physician teams. | Travel does not equal evidence. Demand manufacturing certificates, ethics approval, adverse-event data, published outcomes and continuity-of-care plan at home. |
| Germany / Switzerland / Europe | Advanced hospital systems and some private regenerative clinics. EU advanced therapy rules are complex and country-specific. | Distinguish hospital-approved therapies from private experimental interventions. |
| Japan | PMDA lists March 2026 approvals for AMCHEPRY (raguneprocel), for motor symptoms of Parkinson's disease inadequately responsive to conventional medicines including levodopa, and RiHEART, for severe ischemic-cardiomyopathy heart failure inadequately responsive to standard care. Both are iPSC-derived products with conditional, seven-year approvals. | Approved for narrow indications under conditions, not established universal cures. Official reviews require further efficacy evaluation and all-patient surveillance at appropriately equipped specialist institutions. These approvals do not authorize other clinic products or imply approval in Canada or the U.S. Clarified September 21; approvals themselves date to March. |
| South Korea / China | Active regenerative medicine ecosystems with different approval pathways, trials and commercial offerings. | Check local approval status, international trial registration, language-accessible consent forms and long-term follow-up. |
Risks: the list patients are not always sold
- Infection: contamination, poor processing, injection procedure risk, immune suppression after transplant.
- Blindness and tissue damage: FDA has reported blindness after unapproved regenerative products.
- Tumor formation / abnormal growth: especially concerning for poorly characterized or proliferative cells.
- Immune reaction: donor cells can trigger immune responses; allogeneic transplant can cause graft-versus-host disease.
- Clotting / embolic risks: IV cell products can interact with circulation and lungs.
- Procedure injury: spinal, joint, tendon or eye injections can damage delicate structures.
- False hope / delayed care: a patient may postpone proven treatment while pursuing expensive unproven therapy.
- Financial harm: travel, repeat dosing, add-ons, no insurance coverage, and no refund if benefit does not occur.
- Data opacity: testimonials without denominator: you hear from the success stories, not all the people who paid and did not improve.
Questions to ask before paying any clinic
- What exact cell product is used: bone marrow concentrate, adipose-derived stromal vascular fraction, cultured MSCs, cord tissue cells, exosomes, iPSC-derived cells, or something else?
- Is it autologous or donor-derived? If donor-derived, how are donors screened and matched?
- Is it minimally manipulated or culture-expanded? Where is it processed?
- Is the treatment approved by FDA/Health Canada/EMA for my diagnosis, or is it a registered clinical trial?
- Where is the trial registration number, ethics board approval, adverse-event history and published peer-reviewed outcome data?
- What is the total price including travel, labs, imaging, follow-up, repeat dosing, complications and medications?
- What outcome will be measured: pain scale, imaging, walking distance, blood markers, relapse-free survival, immune markers, quality of life?
- What happens if I get an infection, clot, flare, neurologic symptom or disease progression after returning home?
- Can I speak to an independent physician not financially tied to the clinic?
Managing expectations
Stem cells may become one of the most important medical toolkits of this century. Some uses are already established. Some may transform orthopedics, autoimmune disease, neurodegeneration, diabetes, heart repair and organ regeneration. But the field is not advanced by pretending every injection is a cure.
The honest position is stronger: stem cells are real, but specificity matters. The right cells, for the right disease, made under the right controls, delivered by the right specialists, measured by the right outcomes, can be medicine. The wrong product, sold by the wrong clinic, for the wrong claim, can be expensive theatre — or harm.
Source links
- Managing Expectations source note: September 14, 2026 weekly stem-cell update
- NEJM / PubMed: exa-cel in children with transfusion-dependent β-thalassemia or sickle cell disease
- Cell / PubMed: glycocalyx-edited MSC therapy in advanced osteoporosis
- Stem Cell Reports / PubMed: MSC responder analysis in knee osteoarthritis
- Managing Expectations source note: September 7, 2026 weekly stem-cell update
- FDA warning letter: R3 Medical Companies
- FDA: warning about serious risks from unapproved human cell/tissue products
- ClinicalTrials.gov: STEM-PARK Parkinsonism trial registry lead
- Managing Expectations source note: August 31, 2026 weekly stem-cell update
- PubMed: availability and pricing of orthobiologic knee injections in suburban New York
- PubMed: iPSCs from discovery to translation
- Managing Expectations source note: July 27, 2026 weekly stem-cell update
- Nature Medicine / PubMed: iPSC-derived neural progenitor cell therapy for subacute spinal cord injury, phase 1 long-term follow-up
- PubMed: MSC therapy for Alzheimer’s disease systematic review and meta-analysis
- Managing Expectations source note: July 6, 2026 weekly stem-cell update
- FDA: regenerative medicine patient and consumer information
- FDA: approved cellular and gene therapy products
- NIH: Stem Cell Basics
- NCI: stem cell and bone marrow transplants for cancer
- AAOS: use of stem cells in orthopaedics
- ISSCR: Guidelines for Stem Cell Research and Clinical Translation
- Health Canada: warning on unauthorized cell therapies
- Broder et al.: cost of hematopoietic stem-cell transplantation
- Majhail et al.: costs of autologous and allogeneic HCT
- CNN: Jack Nicklaus stem-cell therapy report
- ESPN: Peyton Manning / miracle-cure framing
- Local source note
Health source library
Back to the Managing Expectations health section: source-grounded reviews of medical claims, papers, films and viral health narratives.
Back to Health